{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-065311","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.353236+00:00","generated_at":"2026-06-18T06:54:26.728423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akebia reports 2022 Auryxia revenue $177.1M (+24.5% YoY); net loss narrows to $92.6M","bullets":["Q4 2022 net product revenue $49.7M (+18.1% YoY); full-year $177.1M, driven by pricing and payer mix.","Full-year net loss $92.6M, down from $282.8M in 2021; cash $90.5M at year-end.","Positive CHMP opinion for vadadustat (Vafseo) in Europe; potential EC approval by May 2023.","2023 Auryxia net product revenue guidance set at $175-180M, reflecting cautious market outlook.","Regained vadadustat rights globally; submitted FDA Formal Dispute Resolution Request in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-065311","json":"https://secwatch.observer/filing/0001193125-23-065311.json","markdown":"https://secwatch.observer/filing/0001193125-23-065311.md","text":"https://secwatch.observer/filing/0001193125-23-065311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/d367644d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:54:26.728423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38828c174faa9a32e227f0d74e4e9f029bdc4d73","claim":"Akebia Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $292.6 million.","evidence_excerpt":"Total revenue was $55.2 million in the fourth quarter of 2022 compared to $59.6 million for the fourth quarter of 2021, and $292.6 million for the full-year 2022 compared to $213.6 million for full-year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$292.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b50ed0c7383ea1ecafefb051a2530bbfa3f7f908","claim":"Akebia Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $55.2 million.","evidence_excerpt":"Total revenue was $55.2 million in the fourth quarter of 2022 compared to $59.6 million for the fourth quarter of 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$55.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e76867712fa70bb2612a9628f77a31927cd02659","claim":"Akebia Therapeutics, Inc. reported 2023 results: revenue $175-$180 million. Guidance initiated.","evidence_excerpt":"Sets 2023 Auryxia net product revenue guidance at $175-$180M","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"$175-$180 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}